首页> 美国卫生研究院文献>Scientific Reports >On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay
【2h】

On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay

机译:软组织肉瘤球体的片上放疗和化疗联合测试以利用流式细胞术和克隆形成试验研究细胞死亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Radiotherapy (RT) and chemotherapy (CT) are the major therapeutics to treat cancer patients. Conventional in vitro 2D models are insufficient to study the combined effects of RT and CT towards optimized dose selection or drug screening. Soft-tissue sarcomas (STS) are rare cancers with profound social impacts as they affect patients of all ages. We developed a microfluidic device to form and culture STS spheroids to study the combined cytotoxicities of RT and CT. Uniformly-sized spheroids of two different cell lines, STS 93 and STS 117, were formed in the device. RT doses of 0.5 Gy, 2 Gy, and 8 Gy were used in combination with CT, doxorubicin at 2 µM and 20 µM. The spheroids culture chambers within the device were arranged in a 3 × 5 matrix form. The device was made “peelable”, which enabled us to collect spheroids from each treatment condition separately. Collected spheroids were dissociated into single cells and evaluated using flow cytometry and clonogenic assays. Through this workflow, we observed that STS 93 spheroids treated with doxorubicin die through apoptosis, whereas RT induced death through other pathways. Spheroids from the p53 mutant STS 117 cell line were more resistant to RT and doxorubicin. The developed device could be used for the discovery of new drugs and RT synergies.
机译:放射疗法(RT)和化学疗法(CT)是治疗癌症患者的主要疗法。传统的体外2D模型不足以研究RT和CT对优化剂量选择或药物筛选的综合作用。软组织肉瘤(STS)是罕见的癌症,具有深远的社会影响,因为它们影响各个年龄段的患者。我们开发了一种微流体装置来形成和培养STS球体,以研究RT和CT的联合细胞毒性。在设备中形成了两个不同细胞系STS 93和STS 117的大小均一的球体。 0.5 µGy,2 µGy和8 µGy的RT剂量与CT,阿霉素(2µµM和20µµM)结合使用。装置内的球状培养室以3××5矩阵形式排列。该设备被制成“可剥离的”,这使我们能够分别收集每种治疗条件下的球状体。将收集的球体解离成单个细胞,并使用流式细胞仪和克隆形成分析进行评估。通过该工作流程,我们观察到用阿霉素处理的STS 93球体通过凋亡而死亡,而RT通过其他途径诱导死亡。来自p53突变STS 117细胞系的球体对RT和阿霉素的耐药性更高。开发的设备可用于发现新药和RT协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号